12:32 PM EST, 11/12/2025 (MT Newswires) -- Kalvista Pharmaceutical's drug Ekterly (sebetralstat) is off to a strong start since its July launch, notes Stifel Canada. DRI Healthcare Trust (DHT-UN.TO) last year acquired a royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista for a purchase price of up to US$179 million.

New patient starts at October-end, totaled 937 (up ~100% since the September update, which included only July and August). Starts originated from 423 unique prescribers and already covers~10% of hereditary angioedema (HAE) patients in the U.S. in a short period since the launch.

"We continue to be encouraged by the performance and expect upcoming quarters to offer increasingly compelling commercial prospects (supported by KALV's now $309 million in cash), validating DRI's first pre-FDA approved royalty investment. "We believe the drug could be a leading asset in DRI's royalty portfolio and conservatively assign ~C$2/sh in value."

DRI Healthcare is rated Buy, with a C$20 price target.

Price: 15.30, Change: +0.03, Percent Change: +0.20